LambdaTest Partners with LinkedIn to Offer Test Automation Professional Certificate on LinkedIn Learning
6.3.2023 19:00:00 EET | Business Wire | Press release
LambdaTest, the leading digital experience testing cloud platform, has partnered with LinkedIn to offer the LambdaTest Test Automation Professional Certificate exclusively available on LinkedIn Learning, as part of its mission to support the testing and QA community.
Through this Professional Certificate course, learners will acquire fundamental knowledge of test automation, including various tools and best practices, in a highly engaging manner from Meaghan Lewis, Technical Program Manager at Microsoft.
More importantly, learners will be able to implement and optimize test automation in their jobs after this course. To earn their LambdaTest Test Automation Professional Certificate, learners will have to complete all courses and content in the learning path and pass the final exam. Learners can access their certificates immediately after they pass the final exam and seamlessly showcase their certificate on LinkedIn.
"We are excited to partner with LambdaTest to provide our customers and learners additional, credible paths to upskilling as well as broaden the audience for the LambdaTest Test Automation Professional Certificate to the world’s largest talent marketplace," said Dan Brodnitz, Sr. Director of Global Content Strategy at LinkedIn Learning.
As LinkedIn Learning students for the LambdaTest Test Automation Professional Certificate, learners can get free trial access to the LambdaTest platform. This enables learners to get hands-on experience and implement the concepts.
“Enterprises, all over the world, are automating their testing to ensure a better digital experience for their users. Learning test automation will open up various career avenues for learners. We are also happy to offer free access to the LambdaTest platform to enable students to get hands-on experience. We are excited to play our role in enabling thousands of learners to achieve their career goals,” said Maneesh Sharma, Chief Operating Officer, LambdaTest.
LambdaTest recently announced the launch of digital experience testing cloud for enterprises. The offering will enable enterprises to accelerate their digital transformation by providing a best-in-class, 360-degree test execution and orchestration platform coupled with insightful test analytics and customizable deployment options.
Also, Satya Nadella, Chairman & CEO of Microsoft, delivered the keynote address at the Microsoft Future Ready Technology Summit 2023, Bengaluru, where he said that “LambdaTest is doing for test automation what Kubernetes did for container orchestration - creating that next level of efficiency around test automation so that people can actually focus on testing versus test orchestration.”
To know more, visit: https://www.lambdatest.com/certifications/linkedin-learning
Notes to the editor
For further information please contact the LambdaTest press office: press@lambdatest.com.
About LambdaTest
LambdaTest is a leading digital experience testing cloud that helps developers and testers ship code faster. Over 10,000+ enterprise customers and 2+ million users across 130+ countries rely on LambdaTest for their testing needs.
LambdaTest platform provides secure, scalable, and insightful test orchestration for customers at different points in their DevOps (CI/CD) lifecycle:
● Cross Browser Testing Cloud
LambdaTest test execution platform allows users to run both manual and automated tests across 3000+ different browsers, real devices, and operating system environments. It enables developers to test their websites, web applications, and native apps without requiring to install or maintain an internal lab of virtual machines, real devices, emulators, or simulators.
● Real Device Testing Cloud
With LambdaTest’s Real Devices Testing Cloud, you can now test unhandled errors, UI/UX, performance, and functionality of your native, web, and hybrid apps before they get released into production. Test on the widest range of mobile and OTT devices (iOS, Android, iPad, Amazon Fire TV, Roku TV & Apple TV). With seamless cross-functional team collaboration across the mobile app development lifecycle, you can release quality mobile apps in shorter development cycles which enables you to innovate and scale rapidly.
● Continuous Testing Cloud - HyperExecute
An IP-led next-gen cloud test execution and orchestration platform that helps enterprises run end-to-end automation tests at the fastest speed possible, thereby enabling them to achieve quicker time-to-market, and deliver a quality digital experience. Achieve 70% faster test execution times and zero flakiness with HyperExecute.
● Visual Regression cloud
Perform Regression Testing in just one click using LambdaTest. Compare the screenshots of your application’s webpages taken from two different browsers to view/detect any visual deviations. Increase browser coverage by running automation scripts on a cloud of 3000+ different desktop and mobile environments.
● Test Intelligence at Scale
Test execution insights are critical for digital transformation as they provide enterprises with more profound insight into the quality of releases and trends. By analyzing the test execution data, LambdaTest's Integrated Test Intelligence delivers enterprises with insights into patterns and trends that can lead to informed decisions about future development and improve application quality.
For more information, please visit: https://lambdatest.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005067/en/
Contact information
LambdaTest press office:
press@lambdatest.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Organon to Present New Research on Access and Value at ISPOR 202615.5.2026 14:30:00 EEST | Press release
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect Organon’s commitment to generating real-world evidence—rooted in lived experiences—that can help inform healthcare decision-making and improve health outcomes across a range of therapeutic areas. “Health economics and outcomes research is critical to ensuring the right treatments reach patients and that health systems can sustain this approach over time,” said Juan Camilo Arjona Ferreira, MD, Head of R&D and Chief Medical Officer at Organon. “At ISPOR 2026, Organon
SES Announces Extraordinary General Meeting of Shareholders15.5.2026 09:30:00 EEST | Press release
SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Extraordinary General Meeting of SES, Société Anonyme, to be held at the Company's registered office at Château de Betzdorf, L-6815 Betzdorf (the "Company"), Luxembourg, on Wednesday 17 June 2026 at 3:00 p.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto - Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hun
Experian Partners With ServiceNow to Scale Trusted Decisioning to Agentic AI15.5.2026 09:00:00 EEST | Press release
Experian, the global data and technology company, and ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today unveil a new global multi-year partnership which harnesses the power of autonomous AI agents across platforms, helping businesses make faster and smarter decisions at scale. Through this partnership, autonomous AI agents can gain the ability to act faster, and more consistently, starting with employee onboarding, third-party risk management and model life cycle governance use cases. A major challenge for global organisations adopting agentic AI is achieving scale, with deployments often constrained by a lack of trusted data. In fact, industry research shows that data limitations are the primary barrier for eight in ten organisations. By connecting trusted intelligence directly into enterprise workflows, this partnership enables agentic AI to scale well beyond pilot deployments. With the Experian Ascend Platform natively connected to the ServiceNow AI Platfo
Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet15.5.2026 04:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III clinical trials evaluating the efficacy and safety of its novel β-lactamase inhibitor nacubactam (development code: OP0595), have been published in The Lancet. The article is entitled “---Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial” (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00596-9/fulltext) Integral-1 is a global, double-blind, randomized Phase III trial (jRCT2031230075) in patients with complicated urinary tract infection or acute uncomplicated pyelonephritis that compared the efficacy and safety of nacubactam co-administered with either cefepime or aztreonam versus imipenem-c
Xsolla and Skich Announce Strategic Partnership to Bring Merchant of Record Payments to an Alternative Mobile Game Marketplace14.5.2026 19:00:00 EEST | Press release
Xsolla, a leading global video game commerce company, today announced a strategic partnership with Skich, an alternative mobile game marketplace operating on iOS in the EU under Apple's Digital Markets Act provisions and on Android globally. Under the agreement, Xsolla will serve as Merchant of Record for in-app purchases and paid game sales distributed through the Skich Store. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514867730/en/ Graphic: Xsolla Skich serves as an alternative to traditional mobile storefronts, offering developers a way to reach players outside platform-controlled distribution channels. The partnership with Xsolla enables Skich to offer a fully compliant payment and commerce layer, with Xsolla managing payment processing, tax collection, refunds, and regulatory compliance on behalf of developers, removing a significant operational and legal barrier for studios looking to distribute through alternat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom